Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 3
2005 1
2006 2
2009 1
2010 2
2011 1
2012 1
2013 4
2017 1
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

15 results

Results by year

Filters applied: . Clear all
Page 1
Drotrecogin alfa (activated) in severe sepsis.
Janes JM, Vangerow B, Costigan TM, Macias WL. Janes JM, et al. Among authors: costigan tm. Lancet Infect Dis. 2013 Feb;13(2):108-9. doi: 10.1016/S1473-3099(12)70309-2. Lancet Infect Dis. 2013. PMID: 23347626 No abstract available.
Pretreatment with prasugrel in non-ST-segment elevation acute coronary syndromes.
Montalescot G, Bolognese L, Dudek D, Goldstein P, Hamm C, Tanguay JF, ten Berg JM, Miller DL, Costigan TM, Goedicke J, Silvain J, Angioli P, Legutko J, Niethammer M, Motovska Z, Jakubowski JA, Cayla G, Visconti LO, Vicaut E, Widimsky P; ACCOAST Investigators. Montalescot G, et al. Among authors: costigan tm. N Engl J Med. 2013 Sep 12;369(11):999-1010. doi: 10.1056/NEJMoa1308075. Epub 2013 Sep 1. N Engl J Med. 2013. PMID: 23991622 Free article. Clinical Trial.
Enhanced active metabolite generation and platelet inhibition with prasugrel compared to clopidogrel regardless of genotype in thienopyridine metabolic pathways.
Braun OÖ, Angiolillo DJ, Ferreiro JL, Jakubowski JA, Winters KJ, Effron MB, Duvvuru S, Costigan TM, Sundseth S, Walker JR, Saucedo JF, Kleiman NS, Varenhorst C. Braun OÖ, et al. Among authors: costigan tm. Thromb Haemost. 2013 Dec;110(6):1223-31. doi: 10.1160/TH13-03-0263. Epub 2013 Sep 5. Thromb Haemost. 2013. PMID: 24009042 Clinical Trial.
Decrease in high on-treatment platelet reactivity (HPR) prevalence on switching from clopidogrel to prasugrel: insights from the switching anti-platelet (SWAP) study.
Saucedo JF, Angiolillo DJ, DeRaad R, Frelinger AL 3rd, Gurbel PA, Costigan TM, Jakubowski JA, Ojeh CK, Duvvuru S, Effron MB; SWAP Investigators. Saucedo JF, et al. Among authors: costigan tm. Thromb Haemost. 2013 Feb;109(2):347-55. doi: 10.1160/TH12-06-0378. Epub 2012 Dec 6. Thromb Haemost. 2013. PMID: 23223867 Clinical Trial.
Intrinsic platelet reactivity before P2Y12 blockade contributes to residual platelet reactivity despite high-level P2Y12 blockade by prasugrel or high-dose clopidogrel. Results from PRINCIPLE-TIMI 44.
Frelinger AL 3rd, Michelson AD, Wiviott SD, Trenk D, Neumann FJ, Miller DL, Jakubowski JA, Costigan TM, McCabe CH, Antman EM, Braunwald E. Frelinger AL 3rd, et al. Among authors: costigan tm. Thromb Haemost. 2011 Aug;106(2):219-26. doi: 10.1160/TH11-03-0185. Epub 2011 Jun 28. Thromb Haemost. 2011. PMID: 21713327 Clinical Trial.
Increased platelet inhibition after switching from maintenance clopidogrel to prasugrel in patients with acute coronary syndromes: results of the SWAP (SWitching Anti Platelet) study.
Angiolillo DJ, Saucedo JF, Deraad R, Frelinger AL, Gurbel PA, Costigan TM, Jakubowski JA, Ojeh CK, Effron MB; SWAP Investigators. Angiolillo DJ, et al. Among authors: costigan tm. J Am Coll Cardiol. 2010 Sep 21;56(13):1017-23. doi: 10.1016/j.jacc.2010.02.072. J Am Coll Cardiol. 2010. PMID: 20846599 Free article. Clinical Trial.
15 results